Nintedanib Gets Fast Track Designation for the Treatment of Scleroderma
source: pixabay.com

Nintedanib Gets Fast Track Designation for the Treatment of Scleroderma

According to a story from BioSpace, the U.S. Food and Drug Administration has given Fast Track designation for nintedanib, which is undergoing testing for the treatment of systemic sclerosis with…

Continue Reading Nintedanib Gets Fast Track Designation for the Treatment of Scleroderma
No-Cost Disease Diagnosis and Immunoglobulin Therapies Now Available to Children with Primary Immunodeficiency Diseases
Source: Pixabay

No-Cost Disease Diagnosis and Immunoglobulin Therapies Now Available to Children with Primary Immunodeficiency Diseases

Primary immunodeficiency diseases account for hundreds of rare and chronic diseases. In children, this may mean that their immune system is non-existent or doesn't perform as expected. To learn more…

Continue Reading No-Cost Disease Diagnosis and Immunoglobulin Therapies Now Available to Children with Primary Immunodeficiency Diseases
The FDA Just Approved a New Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

The FDA Just Approved a New Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy

According to a story from raredr.com, The U.S. Food and Drug Administration (FDA) has recently approved Hizentra as a maintenance therapy for patients with chronic inflammatory demyelinating polyneuropathy. Hizentra is…

Continue Reading The FDA Just Approved a New Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy
The FDA Puts a Halt to Trial for SGT-001, A Treatment in Development for Duchenne Muscular Dystrophy
source: pixabay.com

The FDA Puts a Halt to Trial for SGT-001, A Treatment in Development for Duchenne Muscular Dystrophy

According to a story from raredr.com, the FDA had to order the cessation of Phase II/III trials for the microdystrophin transfer therapy SGT-001, which was in development for the treatment…

Continue Reading The FDA Puts a Halt to Trial for SGT-001, A Treatment in Development for Duchenne Muscular Dystrophy
Close Menu